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18F-FDG Fluorine-18-fluorodeox
64Cu Copper-64
68Ga Gallium-68
89Zr Zirconium-89
90Y Yttrium-90
111In Indium-111
123I Iodine-123
124I Iodine-124
131I Iodine-131
177Lu Lutetium-177
CLI Cerenkov luminescenc
CPP Cell-penetrating pepti
CR Cerenkov radiation
CT Computed tomography
Cy5 Cyanine 5 dye
DT Diphtheria toxin
EGF Epidermal growth fact
FITC Fluorescein isothiocya
GC Gamma camera
HN-J HN-Jumbled
HNSCC Head and neck squam
HPV Human papilloma viru
ICG Indocyanine green
MRI Magnetic resonance im
NIR Near-infrared
OSN Optical surgical naviga
PET Positron-emission tom
PKCε Protein kinase Cε
SPECT Single-photon emission
tomography
siRNA Small interfering RNAwhile simultaneously advancing new therapeutic paradigms for next generation image-guided
surgery, tumor-specific chemotherapeutic delivery and tumor-selective targeted radiotherapy
(i.e., theranostic).
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There are approximately 600,000 new cases of HNSCC
worldwide each year consisting of both high risk HPVþ and
HPVmalignancies.1,2 Routine surgical resection is used for
definitive treatment of HNSCC tumors and is currently
guided only by the surgeon’s vision and palpation. The
current treatment paradigm begins with pre-operative
surgical planning using conventional diagnostic imaging
(CT, MRI and/or PET) imaging followed by targeted visual
resection of the lesion(s) as well as concerning lymph
nodes. Due to the associated complex anatomy, complete
resection of HNSCC is often arduous with little or no real-
time verification of complete surgical resection. Thestandard histopathologic assessment of resected surgical
specimens and their margins can take several days to
complete. Not uncommonly, surgeons are notified days
later that positive surgical margins exist in the resected
specimens. Following definitive unguided surgical resec-
tion, recurrent malignancy occurs in 10%e26% of HNSCC
patients within 5 years, which suggests that some degree of
residual malignancy remained after surgery.3 The presence
of residual malignancy within the surgical bed indicates
that local tumor recurrence is likely and is a poor prognostic
factor.4 In addition, the total number of histologically ma-
lignant lymph nodes removed during the concurrent neck
dissections is a risk factor for local recurrent malignancy as
well as distant metastases.3,5 The overall survival rate for
HNSCC patients has not significantly improved during the
last 20 years with locoregional tumor recurrence/relapse
and distant metastases representing the primary causes of
morbidity and mortality.6
The ability to detect and completely resect the primary
malignancy as well as adequately evaluate for associated
metastatic lymph nodes are critical factors in determining
patient prognosis and subsequent adjuvant therapies. With
respect to conventional imaging assessment for patients
with HNSCC, contrast-enhanced CT or MRI of the site of
primary malignancy in the head and neck is performed, as
well as chest imaging, as part of the initial clinical evalu-
ation. Advanced molecular imaging using Fluorine-18-
fluorodeoxyglucose (18F-FDG) PET/CT or PET/MRI may also
be performed to evaluate the primary tumor and assess for
locoregional and distant metastatic disease. 18F-FDG PET is
used for the diagnosis, staging, and restaging of HNSCC
patients. Unfortunately 18F-FDG PET has a false positive
rate of 23%e30% in HNSCC patients,7e10 which may neces-
sitate further diagnostic evaluation and tissue sampling as
well as potentially delaying therapy. These current limita-
tions and the critical need for improved diagnostic, quan-
titative and prognostic stratification of HNSCC patients
before, during and after definitive therapy are recognized
by the interdisciplinary treatment team.Peptides and antibodies as potential HNSCC
imaging agents
A promising approach to improve both diagnostic sensi-
tivity/specificity and definitive therapy is the evolving field
of tumor-targeting peptides and antibodies. The angiogenic
cyclic RGD peptide cilengitide was one of the first promising
peptides which specifically targeted the avb3 integrin re-
ceptor associated with highly vascular tumors like
HNSCC.11,12 Recent work in BcaCD885 tumor-bearing mice
100 C.L. Wright et al.continues to advance on this track with RGD peptides
conjugated with 800 nm emission quantum dots. These
results demonstrate tumor-to-background ratios of 4.5
compared to 1 with untargeted quantum dots.13
Another promising approach is antibody-mediated tar-
geting of Epidermal Growth Factor (EGF).14 Two antibodies,
cetuximab and panitumumab, have been studied as con-
jugates with the near-infrared (NIR) dye, IRDye800, which is
an 800 nm emitting dye in use in a number of optical sur-
gical navigation (OSN) preclinical agents.15,16 Antibodies
are strong target binders, generally, and these two anti-
bodies are typical with <1 nM kd values. Peak signal in-
tensity in tumors with adequate tumor to background ratios
require longer injection-to-imaging times with the large
antibodies (e.g., 48e72 h post administration) whereas
small peptides like RGD demonstrate peak signal intensity
in less than 24 h. Antibodies also tend to be excreted
through the hepatobiliary system which can limit their
diagnostic utility when used to evaluate for liver and
gastrointestinal lesions but not for the head and neck. Using
orthotopic HNSCC tongue tumor mice, tumor and meta-
static lymph node visualization was judged to be equivalent
with IRdye800-labeled cetuximab and panitumumab.16
Response to cetuximab therapy could also be predicted in
several HNSCC xenograft tumor mice when using cyanine 5
dye (Cy5)-labeled cetuximab.17
Once identified, tumor-targeting peptides and anti-
bodies can be adapted and used for both therapeutic and
diagnostic purposes (i.e., theranostic). The term ‘thera-
nostic’ describes any agent which possesses therapeutic
and diagnostic attributes and is derived from ‘therapeutic’
and ‘diagnostic’. Theranostic agents are an important part
of the evolving field of precision medicine as it enables
personalized patient management for the treatment of
various diseases like HNSCC.18,19HN-1: a prototype tumor-targeting peptide for
HNSCC
The 12 amino acid peptide, HN-1, has been described as a
targeted peptide agentwhich binds to and is internalized into
human HNSCC cells. It was discovered through the screening
of phage-based peptide libraries using human HNSCC tumor
cells. Since the goal was to identify cancer-specific peptides
for tumor cell internalization and potentially drug delivery,
screening was performed at 37 C to facilitate the underlying
tumor-associated endocytotic pathways. Furthermore, the
screening was performed using serum-containing medium to
identify those peptideswhichwere stable in serumandwould
not subsequently degrade when developed and administered
as theranostic agents. These efforts lead to the isolation and
description of a novel peptide sequence (TSPLNIHNGQKL)
which was designated HN-1.20
As initial proof of concept that HN-1 can potentially be
used for tumor-targeted drug delivery, HN-1 has been
conjugated with fluorescein isothiocyanate (FITC) with
photon excitation and emission wavelengths of w495 nm
andw519 nm, respectively, and Cy5 with photon excitation
and emission wavelengths of w650 nm and w670 nm,
respectively. Neither FITC nor Cy5 is imageable by com-
mercial fluorescent imaging system designed for NIRimaging at the 800 nm emission. Both FITC-labeled and Cy5-
labeled HN-1 agents maintain their stability and highly
specific binding to HNSCC tumor cells,6,20 as demonstrated
qualitatively using fluorescence optical imaging. It should
be noted that in these studies, FITC and Cy5 were reported
to be attached to the N-terminal end of the HN-1 pep-
tide,6,20 but there were two distinct labeling sites for the
dyes on HN-1 and the original synthetic chemistry described
for fluorescent labeling was not site-selective. In terms of
cell targeting studies, HN-1 agents have been used in a
variety of malignant/metastatic HNSCC, non-HNSCC, and
non-malignant cells lines (Table 1). FITC-labeled HN-1 when
incubated in mM concentration with a variety of human
HNSCC tumor cell lines demonstrated internal fluorescence
within viable cells and this was both dose-dependent and
time-dependent. Fluorescence uptake was noted by
24e48 h following administration.6,20
Further characterization of FITC-labeled HN-1 indicates
that its intracellular fluorescence can be blocked when
incubated with greater than 200 molar excess (>500 mM) of
unlabeled HN-1 peptide whereas incubation with an irrel-
evant peptide had no effect on intracellular fluorescence.
Likewise, incubating human HNSCC cells with both fluo-
rescein dye and unlabeled HN-1 yielded little detected
fluorescent labeling suggests that intracellular fluorescence
is not mediated by free dye. Additional characterization of
internalized FITC-labeled HN-1 and Texas red-labeled HN-1
within cells suggested that these HN-1 agents may be
compartmentalized within the cytoplasm.20
In terms of the amino acid sequence for HN-1-mediated
cell targeting (Table 2), it has been shown that the addition
of amino acids to both the N-terminal and C-terminal ends
of HN-1 (i.e., HN-2) or simply the N-terminus of HN-1 (i.e.,
HN-3 and HN-1TYR) did not prevent internalization of FITC-
labeled HN-2, HN-3 or HN-1TYR agents.20,21 On the other
hand, rearranging HN-1’s amino acids into clustered groups
of polar amino acids at the N-terminus and apolar amino
acids at the C-terminus (i.e., HN-J or HN-Jumbled) pre-
vented detection of internalized fluorescence.20 Although
these findings suggested that HN-1-mediated cell targeting
was sequence-dependent, it was shown that alternatively
scrambling HN-1’s sequence while maintaining its overall
polar-apolar-polar distribution pattern (i.e., HN-1-scr)
yields intracellular fluorescence comparable to HN-1.22
These results suggest that the specific amino acid
sequence of HN-1 is not essential for tumor-specific binding
and internalization despite the isolation of this specific
peptide sequence during human HNSCC tumor cell
screening. Therefore, it may be that a sequence-specific
peptide receptor is not the tumor-specific target but
rather some other tumor-mediated internalization process.
Further evaluation of the secondary structure of the HN-1
and HN-1-scr peptides compared to HN-J did not eluci-
date any new insights into the potential tumor target since
the structural motifs were distinctly different.22
Despite the lack of an identified HNSCC tumor target for
HN-1, preclinical studies using xenograft tumor mice have
demonstrated that both FITC-labeled HN-1 (administered
via tail vein injection and imaged at 48 h) and Cy5-labeled
HN-1 agents (administered intraperitoneally and imaged at
24 h) are specifically internalized within human HNSCC tu-
mors in vivo (Table 3).6,20 In FITC-labeled HN-1 fluorescing
Table 1 Cell lines used for HN-1 experiments.
Cell lines Fluorescent
uptake
Reference
HNSCC Cells
MDA Tu167a Visualized 20
MDA Tu177 Visualized 20
MDA Tu138 Visualized 20
MDA Tu159 Visualized 20
MDA Tu686 Visualized 20
MDA Tu1986 Visualized 20
UMSCC1 Visualized 6
UMSCC36 Visualized 6
UMB-SCC-745 Little or no
uptake
43
UT-SCC-36 Little or no
uptake
43
UT-SCC-38 Little or no
uptake
43
SCC-25 Visualized 22
Detroit 562 Visualized 22
Non-HNSCC Cells
DU145 Little or no
uptake
20
SW480 Little or no
uptake
20
U373 MG Little or no
uptake
20
MDA-MB231 Visualized 6
SKBR3 Visualized 6
A549 lung carcinoma Little or no
uptake
43
MCF-7 Visualized 21
MDA-MB-468 Visualized 21
ZR-75-1 Visualized 21
Control Cells
HPV-Immortalized human
oral keratinocytes (HOK16B)
Little or no
uptake
20
Immortalized normal oral
epithelial cells (E6/E7-NOE)
Little or no
uptake
6
MCF10A non-tumorigenic
mammary epithelial cells
Little or no
uptake
6
NHDF e Normal Human
Dermal Fibroblasts
Little or no
uptake
21
a Apparently the MDA Tu167 cell line is genetically identical to
the UMSCC-1 cell line and MDATu167 likely represents a UMSCC-1
contamination.62
Table 2 Amino acid sequences of various peptides used in
HN-1 related studies.
Peptide name Sequence Reference
HN-1 based peptides
HN-1 TSPLNIHNGQKL 20
HN-2 GGG-TSPLNIHNGQKL-GGGS 20
HN-3 GSRRASV-TSPLNIHNGQKL 20
HN-1TYR YY-TSPLNIHNGQKL 21
Control peptides
HN-J NQHSKNTLLIGP 20
HN-1-scr LNKQTHGLIPNS 22
Irrelevant
peptide
GIGKFLHSAKKFGKAFVGEIMNS 20
Irrelevant
peptide
GGGRHAYHMHPHHG 22
The polar amino acids are labeled in bold.
Table 3 Xenograft tumor models used influorescent HN-1
imaging studies to date.
Cell lines Fluor HN-1 uptake Reference
MDA Tu177 FITC Visualized 20
MDA Tu167a FITC Visualized 20
UMSCC-1 Cy5 Visualized 6
DU145 FITC Not visualized 20
a Apparently the MDA Tu167 cell line is genetically identical to
the UMSCC-1 cell line and MDATu167 likely represents a UMSCC-1
contamination.62
Advancing theranostics with tumor-targeting peptides 101tumors, there was little labeling of the tumor nuclei which
again supports its internalization into the cytoplasmic
compartment. Further histopathologic evaluation of the
FITC-labeled HN-1 tumors demonstrated fluorescently
labeled cells throughout the tumor and not just at the pe-
riphery. Control studies using (1) fluorescein dye only, (2)
fluorescein dye with unlabeled HN-1 peptide, and (3) FITC-
labeled HN-J control peptide demonstrated little fluores-
cent labeling of tumors. In addition, xenograft mice bearing
only prostate cancer (i.e., non-HNSCC) tumors did not show
fluorescent labeling of the tumors following administration
with FITC-labeled HN-1. In terms of the biodistribution forFITC-labeled HN-1, there was little fluorescence labeling
noted in the brain, heart, lungs, kidneys and liver for both
HNSCC-bearing and non-tumor-bearing mice at 48 h.20
Subsequent xenograft studies using Cy5-labeled HN-1
agents also demonstrated selective labeling of HNSCC tu-
mors while very little uptake was noted in non-tumor
tissues.6Potential for advanced molecular imaging and
theranostics with tumor-targeting peptides
Cerenkov imaging e potential for novel optical
imaging with PET radioisotopes
Arecent and innovative approach for real-time imaging of
lesions containing positron-emitting radioisotopes is the
optical detection of Cerenkov radiation (CR). CR is the
visible and ultraviolet light produced during the process of
either positron- or high-energy therapeutic
betaparticleemission.23e25 Quite simply, CR is produced as
positrons or electrons travel faster than the speed of light
through the aqueous medium of cells, tissues and organs. As
these particles travel through the aqueous medium, the
local electromagnetic field of the water is disrupted and
electrons in the atoms of the water molecules become
displaced. These atoms are polarized by the passing elec-
tromagnetic field of the positron or electron. As the
102 C.L. Wright et al.displaced electrons in the water molecules restore them-
selves to equilibrium, ultraviolet and visible light photons
are emitted and these photons can be detected using
bioluminescence imaging technology. The optical detection
of CR has been recently designated as Cerenkov lumines-
cence imaging (CLI).26 Detectable CLI signals have been
described in vitro for a number of medical positron-
emitting radioisotopes (e.g., 18F) and the therapeutic
betaparticle emitting radioisotope (e.g., Iodine-131
(131I)).27e29 Fig. 1 demonstrates the feasibility of CLI of
the positron-emitting radioisotope Gallium-68 in vitro.
The CLI approach represents new clinical and surgical
opportunities for the real-time detection PET radioactivity
in vitro and in vivo. In particular, images with high spatial
resolution can be obtained within a matter of seconds using
CLI as opposed to several minutes forconventional or
intraoperative nuclear medicine imaging approaches. Cur-
rent CLI systems are also smaller and less costly than con-
ventional nuclear medicine imaging systems. Clinical
applications for human CLI have recently been described
using 131I and 18F-FDG and represent a new and evolving
industry for surgical/interventional imaging systems.30,31
Furthermore, CLI technology will help to facilitate the
pre-clinical development of PET-labeled theranostic agents
like tumor-targeting peptides (e.g., HN-1 and related
peptides).Lu
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Fig. 1 Cerenkov luminescence imaging of the PET radioisotope
generator (Eckert & Ziegler, Berlin, Germany) and its activity was m
The manufacturer specified setting and calibration factor for 68G
taining various activity concentrations of 68Ga were placed within t
system (IVIS 100; Perkin Elmer, Waltham, MA). The IVIS system co
camera, operating at 90 C, and a temperature controlled, light
white-light image and a luminescence image that captured pho
quantified by means of proprietary software (Living Image version 2
Eppendorf tube caps visible on the white-light image. A. CLI image
1136,500 p/sec/cm2/sr. C. There is a positive linear relations
(R2 Z 0.9996). The 68Ga activities ranged from 19 to 1689 kBq and
setting, FOV15, f1, open filter for 30 s (Courtesy of CLW, MVK andOncologic SPECT and PET imaging approaches using
radiolabeled tumor-targeted imaging peptides
Although 18F-FDG PET/CT is routinely used to detect and
stage patients with HNSCC, FDG is not cancer specific.32 At
present, no studies have been published on the radiolabeling
of the HN-1 peptide for diagnostic nuclear medicine imaging
using conventional gamma-emitting (planar scintigraphy,
SPECT, SPECT/CT) or positron-emitting (PET/CT, PET/MRI)
medical radioisotopes. On the other hand, there are several
radiolabeled peptide imaging agents specific for somato-
statin receptor expressing tumors (e.g., neuroendocrine tu-
mors, carcinoid tumors, and paragangliomas of the head and
neck) which have been developed and are in clinical use. The
most commonly used tumor-targeting peptide imaging agent
is Indium-111 (111In)-labeled pentetreotide which binds to
these somatostatin-receptor expressing tumors. 111In-
labeled pentetreotide can be imaged intraoperatively using
portable gamma camera imaging,33 or it can be imaged
conventionally with planar scintigraphy, SPECT and SPECT/
CT imaging.34 This approach requires injection-to-scan times
ranging from 4 to 48 h.
More recently, several 68Ga-labeled DOTA-peptides (e.g.,
DOTATOC, DOTATATE, DOTANOC) have been developed as
PET imaging analogs for various somatostatin receptor
expressing tumors.35e40 The 68Ga-DOTA-peptide agents0
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C
68Ga in vitro. The positron-emitter 68Ga was eluted from a
easured using a calibrated dose calibrator (Capintec CRC 212).
a was used for all measurements. Clear Eppendorf tubes con-
he imaging chamber of a commercial bioluminescence imaging
nsists of a cryogenically-cooled charged couple device (CCD)
-tight imaging chamber. Two sets of images were collected; a
ton output due to Cerenkov luminescence. Photon flux was
.5) using custom regions of interest based on the outlines of the
of 89 kBq of 68Ga. B. ROI analysis of photon flux demonstrated
hip between the 68Ga activity and measured luminescence
were imaged in triplicate using the IVIS 100 high resolution (4)
MFT).
Advancing theranostics with tumor-targeting peptides 103enable much faster imaging with injection-to-scan times
ranging from45 to 90minaswell asmarkedly improved image
resolution for better lesion detectability. Another PET-
labeled agent, Copper-64 (64Cu)-labeled DOTATATE, has
been recently developed and used clinically for the assess-
ment of neuroendocrine tumors.41,42 As expected, both 68Ga-
and 64Cu-labeled PET-labeled DOTA-peptides facilitate
faster imaging with better lesion detectability and lesion
characterization (especially for small lesions) when
compared with standard 111In-labeled pentetreotide ap-
proaches. Moreover, both 68Ga- and 64Cu-labeled DOTA-
peptide agents can be alternatively radiolabeled with ther-
apeutic radioisotopes like Lutetium-177 (177Lu) or Yttrium-90
(90Y) and administered as Peptide Receptor Radionuclide
Therapy (PRRT) for somatostatin-receptor-avid lesions.
It remains to be seen if HNSCC-targeting peptides can be
conjugated with DOTA moieties for subsequent radio-
labeling with 68Ga or 64Cu and still maintain ideal tumor-
specific binding and internalization. Given the relatively
short half-lives for 68Ga and 64Cu (1.1 h and 12.7 h,
respectively) when compared with the published uptake
times for FITC-labeled and Cy5-labeled HN-1 (24e48 h), this
type of approach might not be feasible with HN-1. Alter-
natively, longer lived PET radioisotopes like Zirconium-
89(89Zr, half-life of 3.3 d) and Iodine-124 (124I, half-life of
4.2 d) may be more appropriate strategies for developing
diagnostic PET-labeled HN-1 agents.Theranostics and precision otolaryngology
The current clinical management of HNSCC patients in-
volves a multimodality treatment approach consisting of
surgery, systemic chemotherapy, and radiation therapy.
The relative lack of tumor-targeted approaches for each of
these modalities can contribute to disease recurrence and/
or treatment-related toxicities in HNSCC patients.43 The
paradigm of Precision Otolaryngology incorporates new
tumor-specific targeting strategies to improve the diag-
nostic imaging and quantification of malignant/metastatic
disease burden while enhancing the multimodality thera-
peutic options for individual patients, reducing disease
recurrence/relapse rates and minimizing treatment-
related toxicities. We have already discussed that HNSCC
tumor-targeting peptides like RGDs and HN-1 and various
antibodies have the capability to selectively target tumor
cells when conjugated dye molecules like FITC, Cy5,
IRDye800 and Texas red. This conjugation of optical or
fluorescent dyes to the targeting moiety enables new ap-
proaches beyond the optical detection of tumor (e.g., new
fluorescent image-guided resection of tumor lesions), such
as photodynamic therapies. Therefore, the targeted en-
tities have the potential to become a new class of thera-
nostic agents for HNSCC. Although new image-guided
surgical applications can easily be envisioned, the range of
possible therapeutic approaches is not limited to surgery. If
tumor-targeting peptides can also be conjugated to small
therapeutic molecules or therapeutic radioisotopes, it may
enable more precise delivery of chemotherapeutics and/or
therapeutic radioactivity. Fig. 2 illustrates the theranostic
opportunities for HN-1 and other tumor-targeting peptides
to enable Precision Otolaryngology for HNSCC.New surgical approaches enabled with optical
surgical navigation
Although useful for in vitro and pre-clinical fluorescence
imaging, FITC and Cy5 are suboptimal for clinical fluores-
cence imaging applications but a NIR fluorescent emission
dye like IR800 dye (photon excitation and emission wave-
lengths of w780 nm and w800 nm, respectively) is ideal
due to low tissue auto-fluorescence, better tissue pene-
tration, and minimal in vivo toxicity.15,44 In addition, there
are approximately 7000 optical imaging systems approved
for imaging indocyanine green (ICG), a dicyanine fluores-
cent blood pool marking agent that emits in the NIR just
above 800 nm.45 The application of intraoperative fluores-
cent optical imaging (i.e., OSN) with agents targeted to
cancer cells (e.g., small molecules, peptides or antibodies)
will enhance the surgeon’s detection and resection of pri-
mary tumors and metastatic lesions in real-time, improve
the complete tumor resection rates, and thereby improve
progression-free survival.14,46,47 The accelerating develop-
ment of new OSN technology using cancer specific NIR im-
aging agents is being driven by the unmet clinical need to
more precisely identify, in real-time, tumors and lesions
than is possible with unguided surgical approaches.
The recent development of new OSN systems has trig-
gered a technical evolution away from conventional un-
guided surgical resection to new image-guided surgical
approaches.48,49 Consequently, there is a current need for
the development of fluorescent tumor-targeting agents to
facilitate clinical translation and take advantage of this
emerging technology. This technology enables real-time
detection of fluorescent lesions within the surgical field of
view, facilitates image-guided resection and improved
evaluation of the surgical bed for any residual fluorescence
activity (indicating residual tumor). Given the demon-
strated ability to visualize cancer specific NIR imaging
agents, both in real-time and within the surgical field of
view, it is unlikely that OSN will be replaced by other non-
optical surgical approaches. Existing OSN imaging cameras
have the capability to image fluorescent tumors during
resection, but adoption of this technology is constrained by
the lack of targeted fluorescent imaging agents which
demonstrate accurate imaging concordance with current
diagnostic imaging agents like 18F-FDG. Successful clinical
translation of fluorescent-only imaging agents is therefore
fundamentally limited by differences in mechanisms of
tumor uptake, limits of detection at depths exceeding a
few mm (dues to attenuation and scattering of light),
administered doses in the mmol/kg range (compared to
>100 fold lower for radionuclides) and injection-to-imaging
times when compared with standard diagnostic imaging
agents like 18F-FDG.
New therapeutic approaches using small peptides,
molecules and cytotoxic agents
HN-1-PKCε
It has been noted that protein kinase Cε (PKCε) contributes
to aggressive HNSCC tumor phenotypes and therefore
inhibiting PKCε impairs the invasiveness and motility of
tumor cells.6 As a potential theranostic agent, FITC-labeled
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Precision Otolaryngology for HNSCC:  Theranostic Opportunities for HN-1
Fig. 2 Precision Otolaryngology for HNSCC. The HN-1 peptide as a the ranostic agent (i.e., demonstrates both therapeutic and
diagnostic attributes). HN-1 (center) can potentially be conjugated with NIR fluorescence dyes, PET radioisotopes and non-PET
diagnostic radioisotopes for tumor-specific diagnostic imaging applications. In terms of therapeutics, HN-1 can potentially be
conjugated with various types of chemotherapeutic agents like peptides, toxins and siRNA or therapeutic radioisotopes for PRRT
mediated via alpha or beta particle emissions. In fact, HN-1 has already demonstrated its potential for labeling with multiple
diagnostic and therapeutic moieties. Dual-labeling of HN-1 with fluorescent dyes and chemotherapeutic agents has already been
described in the literature and evaluated in vitro and, to some extent, in vivo. There is potential for dual-labeling HN-1 with both
fluorescent dyes and diagnostic radioisotopes to enable more precise image-guided surgery or fluorescence-augmented radioguided
surgery. There is also potential for dual-labeling HN-1 with diagnostic radioisotopes and chemotherapeutic agents to precisely
localize and quantify the delivery of the theranostic agent to the target lesions. Dual-labeled HN-1 with therapeutic radioisotopes
and chemotherapeutic radiosensitizers is another approach to precisely deliver a high-yield chemoradiotherapy payload to target
tumor lesions.
104 C.L. Wright et al.HN-1 (diagnostic) was conjugated to an inhibitory PKCε
peptide (therapeutic) and was found to inhibit prolifera-
tion, motility and invasion in HNSCC cell lines but had
minimal effect on the control immortalized normal oral
epithelial cells. In principle, these results demonstrate that
HN-1 represents a promising theranostic entity that can
maintain its tumor selectivity despite conjugation of mul-
tiple diagnostic/therapeutic moieties as well as facilitate
the internalization or intracellular delivery of potential
therapeutics.
Cy5-labeled HN-1-PKCε was subsequently used for pre-
clinical studies in HNSCC-bearing xenograft mice. Minimal
fluorescence was noted in HNSCC tumors or normal tissues
when treated with control Cy5-labeled-PKCε (i.e., no HN-
1). Likewise, there was minimal autofluorescence in HNSCC
tumors or normal tissues in untreated mice. On the other
hand, HNSCC tumor fluorescence was greater than 8-fold
higher than normal tissues in mice treated with Cy5-labeled
HN-1-PKCε. Cy5-labeled HN-1-PKCε also reduced overall
HNSCC tumor growth when compared with Cy5-labeled-
PKCε treated or untreated tumor-bearing mice. Again,
these results demonstrate that the HN-1 peptide can serve
as a theranostic agents for HNSCC.6
Although FITC-labeled HN-1 did not demonstrate signif-
icant fluorescent internalization with DU145 (prostatecancer), SW480 (colon cancer) and U373 MG (astrocytoma)
cells,20 FITC-labeledHN-1-PKCε demonstrated significant
fluorescent internalization when applied to two breast
cancer cell lines. Much lower fluorescent internalization
was noted when FITC-labeledHN-1-PKCε was applied to
non-tumorigenic mammary epithelial cells.6 This was the
first observation that HN-1 may not be tumor-specific or
organ-specific but rather cancer-specific. As a cancer-
selective targeting peptide as opposed to a HNSCC-
selective targeting peptide, the potential theranostic ap-
plications for HN-1 increase.
Diptheria toxin/HN-1
In another study, HN-1 was conjugated to diphtheria toxin
(DT) and was found to have cytotoxic effects on the HNSCC
cell lines used whereas the non-HNSCC cells were resistant
to the cytotoxic effects of DT/HN-1. The DT/HN-1 agent
demonstrated a 4-fold increase in tumor cell apoptosis
when compared with tumor cells treated with DT alone.
DT/HN-1 also contributed to dose-dependent inhibition of
HNSCC tumor cell proliferation. This suggests that HN-1
conjugated with DT can selectively deliver DT to HNSCC
cells and its subsequent internalization facilitates its
therapeutic effect. Interestingly, if the translocation
domain of DT is deleted but conjugated to HN-1 (DTDT/HN-
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which suggests that although HN-1 facilitates tumor cell
internalization (possibly via endosomes) it cannot further
translocate DT into the cytoplasm.43 To date, no preclinical
studies have been reported that further evaluate the
impact of DT/HN-1 on tumors in xenograft or orthotopic
models.
HN-1TYR-anti-hRRM2 siRNAR
Another study evaluated the feasibility of using modified
HN-1 constructs to both target cancer cells and deliver
small interfering RNA (siRNA) molecules for anticancer
therapy. In this study, HN-1 was first specifically modified
with the addition of 2 tyrosine residues at the N-terminus
(i.e., HN-1TYR). FITC-labeled HN-1TYR demonstrated fluo-
rescent internalization when incubated with presumed
head and neck cancer KB cells (ATCC CCL-17) but not with
NHDF (normal human dermal fibroblasts) cells.21 Of note,
KB cells were initially believed to be derived from oral
epidermal carcinoma but were subsequently found to
represent HeLa cell contamination (i.e., epithelial cervical
adenocarcinoma) according to the ATCC website.50
Although no other HNSCC cell lines were tested with the
FITC-labeled HN-1TYR agent in this study,21 this correction
implies that the HN-1 peptide may also represent a po-
tential tumor-targeting peptide agent for cervical adeno-
carcinoma but further studies are needed to validate this.
Given that HN-1 internalization had been previously
noted in human breast cancer cells,6 the potential for FITC-
labeled HN-1TYR to serve as a tumor-specific delivery
mechanism for discrete siRNA molecules was evaluated in
human breast cancer cells.21 The intracellular target was
ribonucleotide reductase and therefore anti-hRRM2 siRNA
was conjugated to FITC-labeled HN-1TYR (i.e., HN-1TYR-anti-
hRRM2 siRNAR). The in vitro application of HN-1TYR-anti-
hRRM2 siRNAR partially suppressed the normal expression
levels of hRRM2 in the treated breast cancer cells which
suggests that HN-1 may help to facilitate the selective
internalization of potential anticancer siRNA molecules into
tumor cells. To date, no preclinical studies have been re-
ported that have advanced this promising possibility of
FITC-labeled HN-1TYR or HN-1TYR-anti-hRRM2 siRNAR locali-
zation to breast tumor-bearing xenograft/orthotopic
models.Current challenges and future opportunities for
advancing theranostics and precision
otolaryngology
At present, no ‘HN-1 receptor’ has been identified and
since a scrambled HN-1 peptide (i.e., HN-1-scr) demon-
strated comparable intracellular fluorescence to the native
HN-1,22 it is possible that strict sequence-dependence is not
essential for HN-1-mediated cellular internalization. In
addition, HN-1 has been shown to target/internalize into
other non-HNSCC tumor types. Collectively these findings
suggest that HN-1 may not represent a true tumor-specific
receptor ligand but rather a tumor cell-penetrating pep-
tide (CPP). If HN-1 is a CPP, some potential tumor entry
mechanisms for HN-1 may include membraneglycosaminoglycans, clathrin-dependent endocytosis,
caveolin-associated lipid rafts, and actin/microtubule-
mediated transport processes. Needless to say, additional
studies will be needed to specifically address and elucidate
the membrane target(s) or cellular mechanism(s) that HN-1
peptides exploit for tumor cell entry.51
Despite the fact that HPV has been strongly associated
with the prevalence of HNSCC worldwide, no studies have
yet demonstrated the feasibility of HN-1-mediated uptake
and internalization into HPVþ HNSCC cells or tumors. All
HN-1 studies to date have exclusively used HPV negative
HNSCC cell lines and tumors. At present, there is no ratio-
nale to expect HN-1 mediated uptake and internalization
would be significantly different for HPVþ and HPV HNSCC
tumors but it will be important for future HN-1 studies to
address this for future clinical translation. The observation
that FITC-labeled HN-1TYR internalized into HeLa cells, a
HPVþ cervical adenocarcinoma cell line, provides initial
evidence that the utility of HN-1 will extend to HPVþ
carcinomas.
In the future, the clinical promise and translational
significance of a dual NIR fluorescent and radioactively
labeled theranostic HN-1 agent targeted to HNSCC is that it
will enable:
(1) both pre- and post-surgical advanced molecular im-
aging using gamma/PET imaging systems to specif-
ically detect and precisely localize HN-1-avid
malignant and metastatic lesions. It is conceivable
that such diagnostic HN-1 imaging agents may
improve the staging of HNSCC and more accurately
triage patients to or away from surgery.
(2) Real-time intraoperative NIR fluorescent detection of
HN-1-avid lesions during image-guided resection using
one of the more than 7000 FDA-approved optical
surgical imaging systems. A caveat is that these op-
tical imaging systems are not all of equivalent sensi-
tivity and, at the moment, FDA approval for these
systems are specific to ICG. This will necessitate
Phase III trials with these imaging systems and inter-
est groups are actively investigating these and other
logistic and regulatory issues.52
(3) Alternatively, if the HN-1 agent is labeled with a
diagnostic non-PET radioisotope (e.g., 111In or Iodine-
123 (123I)) then intraoperative optical techniques
using NIR dye could initially guide a surgeon’s resec-
tion in real-time with subsequent intraoperative
gamma imaging and/or hand-held radioactivity
probing of the surgical field to verify complete
resection or redirect the surgeon to areas of persis-
tent radioactivity (i.e., residual tumor or tumor
which is too deep for adequate optical detection).
Radioguided surgical approaches have been demon-
strated and are clinically effective.33,53e55
(4) Ex vivo gamma/PET and fluorescent imaging of
resected specimens for more rapid and precise radi-
ologicepathologic correlation and assessment.
(5) Following surgical resection, any residual microscopic
malignancy or metastatic lesions could be further
treated using a therapeutic radioisotope (e.g., 90Y,
131I, 177Lu) conjugated to the HN-1 peptide agent.
106 C.L. Wright et al.Since external radiation therapy is often used in the
treatment of HNSCC, this targeted approach for
subsequent targeted PRRT for residual microscopic
disease maybe a useful adjunct to existing therapy
and improve patient progression-free survival.
Accurate clinical correlation of the gamma/PET radio-
activity and NIR fluorescent signals could be achieved most
reliably when the same targeted HN-1 molecule be dual-
labeled and used even though the limits of detection and
useful imaging concentrations for PET and fluorescent im-
aging are orders of magnitude different. Targeted dual-
labeled HN-1 agents are transformative technology that will
enable new diagnostic and therapeutic paradigms for
HNSCC and potentially other cancer patients. While this
concept of dual-modality cancer agents has been previously
reviewed,56,57 true dual-function molecular cancer agents
are rare.58e61
Conclusions
The treatment of HNSCC is complex and necessitates close
collaboration among various medical specialties including
nuclear medicine, interventional and diagnostic radiology,
otolaryngology, pathology, surgical/medical oncology and
radiation oncology. There is an unmet clinical need to both
improve non-invasive diagnostic imaging and image-guided
surgical methodologies as well as targeted chemothera-
peutic and radiotherapeutic approaches for HNSCC patients
(i.e., Precision Otolaryngology). Theranostic tumor target-
ing peptides represent transformative technology and will
enable consistent, quantifiable in vivo imaging that can be
clinically translated and easily implemented for diagnostic/
therapeutic assessment by the treatment team.
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